Effects of alcoholism typology on response to naltrexone in the COMBINE study

Alcoholism: Clinical and Experimental Research

Volumn 33, Issue 1, 2009, Pages 10-18

  Bogenschutz, Michael P ^a,b   Scott Tonigan, J ^a   Pettinati, Helen M ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alcoholism; Naltrexone; Pharmacotherapy; Randomized clinical trial; Typology

Indexed keywords

NALTREXONE; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ALCOHOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; TEMPERANCE;

EID: 58149117745     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00804.x     Document Type: Article

References (46)

1. Anton RF, Moak DH, Latham P (1995) The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19 (1 92 99.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, Locastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 : 2003 2017.
3. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65 : 135 144.
4. Babor TF, Hofmann M, Delboca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B (1992) Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 49 : 599 608.
5. Brodman K, Erdman AJ, Lorge I, Wolff HC (1949) The Cornell Medical Index. JAMA 140 : 530 534.
6. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI, Reich T, Schmidt I, Schuckit MA (1994) A new, semi-structured psychiatric interview for use in genetic linkage studies: a report of the reliability of the SSAGA. J Stud Alcohol Suppl 55 : 149 158.
7. Chick J, Aschauer H, Hornik K (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 74 : 61 70.
8. Cloninger CR, Sigvardsson S, Gilligan SB, Von Knorring AL, Reich T, Bohman M (1988) Genetic heterogeneity and the classification of alcoholism. Adv Alcohol Subst Abuse 7 : 3 16.
9. Combine Study Research Group (2003) Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res 27 : 1107 1122.
10. Dundon W, Lynch KG, Pettinati HM, Lipkin C (2004) Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res 28 : 1065 1073.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
12. Gastfriend DR, Donovan D, Lefebvre R, Murray KT (2005) Developing a baseline assessment battery: balancing patient time burden with essential clinical and research monitoring. J Stud Alcohol Suppl 15 : 94 103. discussion 92-93.
13. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31 : 555 563.
14. Hesselbrock M, Babor T, Hesselbrock V, Meyer R, Workman K (1983) "Never believe an alcoholic?" On the validity of self-report measures of alcohol dependence and related constructs. Inter J Addict 18 : 678 691.
15. Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75 : 34 56.
16. Johnson BA, Roache JD, Javors MA, Diclemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 284 : 963 971.
17. Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O'Brien CP (2007) A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 27 : 344 351.
18. Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K (2005) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 11 : 83 91.
19. Kiefer F, Jimenez-Arriero MA, Klein O, Diehl A, Rubio G (2008) Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol 13 : 124 129.
20. Kranzler HR, Burleson JA, Brown J, Babor TF (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 20 : 1534 1541.
21. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 : 1734 1739.
22. Lesch OM, Bonte W, Kefer RJRM, Musalek MAN, Sprung R, Walter H (1989) A new typology in chronic alcoholism and its biological markers. Alcohol Alcohol 24 : 380.
23. Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H (2001) The European acamprosate trials: conclusions for research and therapy. J Biomed Sci 8 : 89 95.
24. Litt MD, Babor TF (2001) Alcoholic typology as an attribute for matching clients to treatment, in Project MATCH Hypotheses: Results and Causal Chain Analyses, Project MATCH Monograph Series, Vol. 8 (Wirtz RLPW ed. 223 238. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
25. Litt MD, Babor TF, Delboca FK, Kadden RM, Cooney NL (1992) Types of alcoholics, II. Application of an empirically derived typology to treatment matching. Arch Gen Psychiatry 49 : 609 614.
26. McConnaughy EA, Prochaska JO, Velicer WF (1983) Stages of change in psychotherapy: measurement and sample profiles. Psych Theory Res 20 : 368 375.
27. Miller WR (ed 2004) Combined Behavioral Intervention Manual: A Clinical Research Guide for Therapists Treating People With Alcohol Abuse and Dependence (Vol. 1). National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
28. Miller WR, Del Boca FK (1994) Measurement of drinking behavior using the Form 90 family of instruments. J Stud Alcohol Suppl 12 : 112 118.
29. Milller WR, Tonigan JS, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Test manual (Vol. 4). US Government Printing Office, Rockville, MD.
30. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10 : 258 268.
31. Oslin DW, Berrettini W, Kranzler HR, Pettinati HM, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with therapeutic response in alcohol dependent patients treated with naltrexone. Neuropsychopharmacology 28 : 1546 1552.
32. Penick EC, Nickel EJ, Powell BJ, Liskow BI, Campbell J, Dale TM, Hassanein RE, Noble E (1999) The comparative validity of eleven alcoholism typologies. J Stud Alcohol 60 : 188 202.
33. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SM, Oslin DW, Kampman KM, Dackis CA (2006) The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J Clin Psychopharmacology 26 : 610 625.
34. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 24 : 1041 1049.
35. Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ (2005a) A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 15 : 170 178.
36. Pettinati HM, Weiss RD, Miller WR, Donovan DM, Ernst DB, Rounsaville BJ (2004) Medical Management (MM) Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
37. Pettinati HM, Zweben A, Mattson ME (eds 2005b) The COMBINE study: conceptual, methodological and practical issues in a clinical trial that combined medications and behavioral treatments. J Stud Alcohol Suppl 15.
38. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64 : 1069 1077.
39. Rohsenow DJ, Miranda R Jr., Mcgeary JE, Monti PM (2007) Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol 15 : 272 281.
40. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T (2005) Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 40 : 227 233.
41. Schuckit MA, Tipp JE, Smith TL, Shapiro E, Hesselbrock VM, Bucholz KK, Reich T, Nurnberger JI Jr. (1995) An evaluation of type A and B alcoholics. Addiction 90 : 1189 1203.
42. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91 (3 199 209.
43. Srisurapanont M, Jarusuraisin N (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8 : 267 280.
44. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr., Mcgeary JE, Mackillop J, Swift RM, Abrams DB, Shiffman S, Paty JA (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32 : 58 66.
45. Verheul R, Lehert P, Geerlings PJ, Koeter MW, Van Den Brink W (2005) Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 178 : 167 173.
46. Yoshino A, Kato M (1996) Prediction of 3-year outcome of treated alcoholics by an empirically derived multivariate typology. Am J Psychiatry 153 : 829 830.